Table 3.

Antitumor activity of CDP-TubA in the H460 human non–small cell lung carcinoma xenograft model in nude mice

GroupTreatment regimen
Median
T-C%TGDStatistical significance*
MTV
Statistical significance
Regressions
Mean BW
TR
Agentmg/kgScheduleTTEvs G1vs G5vs G6Day 25vs G1vs G5vs G6PRCRTFSNadirDeaths
1Vehicleqwk ×320.32144 ± 4540000
2Tubulysin0.025qwk ×323.73.417ns§ns1799 ± 834ns0110
3Paclitaxel30qod ×535.915.677nsns884 ± 388ns011−17.5% Day 140
4Vinblastine8qwk ×342.422.1109§nsns752 ± 563nsns011−6.7% Day 50
5CDP-TubA6qwk ×352.332.0158144 ± 74.7011−7.9% Day 30
6CDP-TubA3qwk ×343.222.9113§847 ± 441000−0.4% Day 40
  • NOTE: Potency was evaluated using log-rank testing on the time it took for individual tumors to reach a predetermined endpoint (TTE) of 2,000 mm3 and by comparing the mean tumor volume (MTV) for different treatment groups when tumors of vehicle treated animals reached 2,000 mm3 (day 25). Ten animals per group were treated. CDP-TubA (batch #2) doses are in tubulysin equivalents.

    MTV, mean tumor volume ± SD (mm3) on the day the vehicle control group mean tumor volume reached the predetermined endpoint of 2,000 mm3.

  • * Statistical significance = Logrank test.

  • Statistical significance = ANOVA w. Tukey's post test.

  • P < 0.001.

  • § P < 0.01.

  • P < 0.05.